This is consistent with the sustained durable tumour regressions seen with selumetinib plus ABT‐263 in KRAS‐mutant colorectal xenograft models and KRAS‐driven lung cancer genetically engineered mouse models 86. This evidence concerns the gene KRAS and lung carcinoma.